<DOC>
	<DOCNO>NCT00005585</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . It yet know regimen combination chemotherapy effective childhood acute lymphoblastic leukemia . PURPOSE : This randomized phase III trial compare different regimen combination chemotherapy see well work treat child acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy toxicity short methotrexate infusion v long infusion patient low-risk acute lymphoblastic leukemia . - Compare efficacy regimens methotrexate , without multidrug intensification , patient . OUTLINE : This randomize , multicenter study . Patients stratify accord genetics ( stratum 1 : trisomy 4/10 TEL/AML1 v stratum 2 : TEL/AML1 without trisomy 4/10 ) . All patient receive induction therapy ( week 1-4 ) another protocol ( POG-9900 ) . Stratum 1 - Consolidation therapy begin week 5 . Patients randomized arm I II . - Arm I : Patients receive methotrexate ( MTX ) IV 24 hour day 1 oral leucovorin calcium ( CF ) every 6 hour 3 dos begin 42 hour initiation MTX infusion week 7 , 10 , 13 , 16 , 19 . - Arm II : Patients receive MTX IV 4 hour day 1 oral CF arm I week 7 , 10 , 13 , 16 , 19 . - Patients arm I II also receive MTX intrathecally ( IT ) week 7 , 10 , 13 , 16 , 19 , 22 ; oral mercaptopurine ( 6-MP ) daily week 5-24 ; oral dexamethasone ( DM ) twice daily day 1-7 week 8 17 ; vincristine ( VCR ) IV day 1 week 8 , 9 , 17 , 18 . Stratum 2 - Consolidation therapy begin week 5 delay intensification therapy begin week 16 . Patients randomize delayed intensification delay intensification . Patients randomize delayed intensification randomize consolidation therapy arm I II . Patients randomize delayed intensification randomize arm III IV . Patients trisomy 4/10 randomized arm III IV . - Arm III : Patients receive MTX IV CF arm I week 7 , 10 , 13 , 24 , 27 , 30 . - Arm IV : Patients receive MTX IV CF arm II week 7 , 10 , 13 , 24 , 27 , 30 . - Patients arm III IV also receive oral 6-MP daily week 5-13 begin week 24 continue end consolidation ; MTX IT week 7 , 10 , 13 , 16 , 20 , 21 , 30 ; oral DM twice daily day 1-7 week 8 , 16-18 , 28 ; VCR IV day 1 week 8 , 9 , 16-18 , 28 , 29 ; pegaspargase intramuscularly week 16 ; daunorubicin IV day 1 week 16-18 ; cyclophosphamide IV day 1 week 20 ; cytarabine IV subcutaneously day 2-5 week 20 21 ; oral thioguanine daily day 1-14 week 20 21 . All patient receive continuation therapy begin week 25 arm I II week 33 arm III IV continue week 130 arm . Continuation - Arms I II : Patients receive oral 6-MP daily week 25-130 ; oral DM twice day day 1-7 VCR IV day 1 8 week 25 , 41 , 57 , 73 , 89 , 105 ; oral MTX weekly week 25-130 ( except week IT MTX ) ; MTX IT week 25 , 37 , 49 , 61 , 73 , 85 , 97 , 109 . - Arms III IV : Patients receive oral 6-MP daily week 33-130 ; oral DM twice day day 1-7 VCR IV day 1 8 week 41 , 57 , 73 , 89 , 105 ; oral MTX weekly week 33-130 ( except week IT MTX ) ; MTX IT week 37 , 49 , 61 , 73 , 85 , 97 , 109 . Patients follow every 2 month 2 year , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 902 patient accrue study within 3.22 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell precursor acute lymphoblastic leukemia Registered POG9900 Classification Study Registered within 7 day document complete response ( CR ) induction therapy day 29 , 2 week induction require , within 7 day CR determination Classified lowrisk : WBC le 50,000/mm^3 Age 1 9 No adverse translocation [ E2APBX1 , ( 1 ; 19 ) BCR/ABL , ( 9 ; 22 ) ; MLL rearrangement ] No CNS 3 disease ( CSF WBC least 5/mm^3 blast present ) No testicular disease At least one follow present : TEL/AML1 , ( 12 ; 21 ) Simultaneous trisomy chromosomes 4 10 PATIENT CHARACTERISTICS : Age : 1 9 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>